Cila Therapeutics
Safia K. Rizvi is the CEO & Founder of Cila Therapeutics. Previously, Safia was Managing Director at The Blue Group, a Global strategic advisory and consulting practice for Life Science Industry.
Safia earned her MBA in Health/Health Care Management from The Wharton School in 2003.
Cila Therapeutics
Cila Therapeutics is a clinic-ready stage, a biotechnology company developing new inhaled therapies for respiratory diseases, leading with an inhaled treatment of a rare genetic disorder, Primary Ciliary Dyskinesia, or PCD.